This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
ELISA/assay
product name :
Human TIMP-2 Quantikine ELISA Kit
catalog :
DTM200
quantity :
1 Kit
price :
655 USD
citations: 36
Reference
de Rooij E, Hoogeveen E, Romijn F, van der Kooy S, Veighey K, Dekker F, et al. Urinary beta-2 microglobulin increases whereas TIMP-2 and IGFBP7 decline after unilateral nephrectomy in healthy kidney donors. Sci Rep. 2024;14:12901 pubmed publisher
Tsomidis I, Notas G, Xidakis C, Voumvouraki A, Samonakis D, Koulentaki M, et al. Enzymes of Fibrosis in Chronic Liver Disease. Biomedicines. 2022;10: pubmed publisher
Nasiri Ansari N, Spilioti E, Kyrou I, Kalotychou V, Chatzigeorgiou A, Sanoudou D, et al. Estrogen Receptor Subtypes Elicit a Distinct Gene Expression Profile of Endothelial-Derived Factors Implicated in Atherosclerotic Plaque Vulnerability. Int J Mol Sci. 2022;23: pubmed publisher
Peterson T, Landon C, HABERLEN S, Bhondoekhan F, Plankey M, Palella F, et al. Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV. BMC Cardiovasc Disord. 2022;22:393 pubmed publisher
Wu J, Sun Z, Liu S, Chen Z, Yuan Z, Zou M, et al. The ASIC3-M-CSF-M2 macrophage-positive feedback loop modulates fibroblast-to-myofibroblast differentiation in skin fibrosis pathogenesis. Cell Death Dis. 2022;13:527 pubmed publisher
Tao X, Chen C, Luo W, Zhou J, Tian J, Yang X, et al. Combining renal cell arrest and damage biomarkers to predict progressive AKI in patient with sepsis. BMC Nephrol. 2021;22:415 pubmed publisher
Moriya K, Nishimura N, Namisaki T, Takaya H, Sawada Y, Kawaratani H, et al. Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis. J Clin Med. 2021;10: pubmed publisher
Esmeijer K, Schoe A, Ruhaak L, Hoogeveen E, Soonawala D, Romijn F, et al. The predictive value of TIMP-2 and IGFBP7 for kidney failure and 30-day mortality after elective cardiac surgery. Sci Rep. 2021;11:1071 pubmed publisher
Waszczykowska A, Podgórski M, Waszczykowski M, Gerlicz Kowalczuk Z, Jurowski P. Matrix Metalloproteinases MMP-2 and MMP-9, Their Inhibitors TIMP-1 and TIMP-2, Vascular Endothelial Growth Factor and sVEGFR-2 as Predictive Markers of Ischemic Retinopathy in Patients with Systemic Sclerosis-Case Series Report. Int J Mol Sci. 2020;21: pubmed publisher
Morad G, Daisy C, Otu H, Libermann T, Dillon S, Moses M. Cdc42-Dependent Transfer of mir301 from Breast Cancer-Derived Extracellular Vesicles Regulates the Matrix Modulating Ability of Astrocytes at the Blood-Brain Barrier. Int J Mol Sci. 2020;21: pubmed publisher
Stanciu A, Zamfir Chiru Anton A, Stanciu M, Pantea Stoian A, Nitipir C, Gheorghe D. Serum melatonin is inversely associated with matrix metalloproteinase-9 in oral squamous cell carcinoma. Oncol Lett. 2020;19:3011-3020 pubmed publisher
Kobus A, Bagińska J, Łapińska Antończuk J, Ławicki S, Kierklo A. Levels of Selected Matrix Metalloproteinases, Their Inhibitors in Saliva, and Oral Status in Juvenile Idiopathic Arthritis Patients vs. Healthy Controls. Biomed Res Int. 2019;2019:7420345 pubmed publisher
Zhang D, Peng Y, Zhang H, Ma J, Zhao M, Yin S, et al. Basilar Artery Tortuosity Is Associated With White Matter Hyperintensities by TIMP-1. Front Neurosci. 2019;13:836 pubmed publisher
Dekker S, Ruhaak L, Romijn F, Meijer E, Cobbaert C, de Fijter J, et al. Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor-Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients. Kidney Int Rep. 2019;4:833-841 pubmed publisher
Schmitt R, Tscheuschler A, Laschinski P, Uffelmann X, Discher P, Fuchs J, et al. A potential key mechanism in ascending aortic aneurysm development: Detection of a linear relationship between MMP-14/TIMP-2 ratio and active MMP-2. PLoS ONE. 2019;14:e0212859 pubmed publisher
Łukaszewicz Zajac M, Gryko M, Pączek S, Szmitkowski M, Kędra B, Mroczko B. Matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor 2 (TIMP-2) in pancreatic cancer (PC). Oncotarget. 2019;10:395-403 pubmed publisher
Ahn M, Kim B, Kim H, Jin J, Yoon H, Hwang J, et al. Anti-cancer effect of dung beetle glycosaminoglycans on melanoma. BMC Cancer. 2019;19:9 pubmed publisher
Wu C, Su M, Wu Y, Hwang J, Lin L. Combination of Plasma Biomarkers and Clinical Data for the Detection of Myocardial Fibrosis or Aggravation of Heart Failure Symptoms in Heart Failure with Preserved Ejection Fraction Patients. J Clin Med. 2018;7: pubmed publisher
Castellano J, Mosher K, Abbey R, McBride A, James M, Berdnik D, et al. Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature. 2017;544:488-492 pubmed publisher
Niño M, Serrano S, Niño D, McCosham D, Cárdenas M, Villareal V, et al. TIMP1 and MMP9 are predictors of mortality in septic patients in the emergency department and intensive care unit unlike MMP9/TIMP1 ratio: Multivariate model. PLoS ONE. 2017;12:e0171191 pubmed publisher
Braicu E, Gasimli K, Richter R, Nassir M, Kummel S, Blohmer J, et al. Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial. Anticancer Res. 2014;34:385-91 pubmed
Braicu E, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kummel S, et al. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin an. Cytokine. 2013;61:755-8 pubmed publisher
Wilcock D, Morgan D, Gordon M, Taylor T, Ridnour L, Wink D, et al. Activation of matrix metalloproteinases following anti-A? immunotherapy; implications for microhemorrhage occurrence. J Neuroinflammation. 2011;8:115 pubmed publisher
Jonsson S, Lundberg A, Kälvegren H, Bergström I, Szymanowski A, Jonasson L. Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris. PLoS ONE. 2011;6:e19340 pubmed publisher
Reikvam H, Hatfield K, Oyan A, Kalland K, Kittang A, Bruserud O. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol. 2010;84:239-51 pubmed publisher
Sesso R, Franco M. Abnormalities in metalloproteinase pathways and IGF-I axis: a link between birth weight, hypertension, and vascular damage in childhood. Am J Hypertens. 2010;23:6-11 pubmed publisher
O Kane C, McKeown S, Perkins G, Bassford C, Gao F, Thickett D, et al. Salbutamol up-regulates matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome. Crit Care Med. 2009;37:2242-9 pubmed publisher
Glass Marmor L, Paperna T, Galboiz Y, Miller A. Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses. J Neuroimmunol. 2009;210:124-7 pubmed publisher
Kapsoritakis A, Kapsoritaki A, Davidi I, Lotis V, Manolakis A, Mylonis P, et al. Imbalance of tissue inhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with inflammatory bowel disease. BMC Gastroenterol. 2008;8:55 pubmed publisher
McKeown S, Richter A, O Kane C, McAuley D, Thickett D. MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J. 2009;33:77-84 pubmed publisher
Glader P, Eldh B, Bozinovski S, Andelid K, Sjostrand M, Malmhall C, et al. Impact of acute exposure to tobacco smoke on gelatinases in the bronchoalveolar space. Eur Respir J. 2008;32:644-50 pubmed publisher
Huh J, Kim D, Oh Y, Shim T, Lim C, Lee S, et al. Is metalloproteinase-7 specific for idiopathic pulmonary fibrosis?. Chest. 2008;133:1101-6 pubmed
Thrailkill K, Bunn R, Moreau C, Cockrell G, Simpson P, Coleman H, et al. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care. 2007;30:2321-6 pubmed
Bodet C, Andrian E, Tanabe S, Grenier D. Actinobacillus actinomycetemcomitans lipopolysaccharide regulates matrix metalloproteinase, tissue inhibitors of matrix metalloproteinase, and plasminogen activator production by human gingival fibroblasts: a potential role in connective tissue destr. J Cell Physiol. 2007;212:189-94 pubmed
Kuyvenhoven J, Molenaar I, Verspaget H, Veldman M, Palareti G, Legnani C, et al. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury. Thromb Haemost. 2004;91:506-13 pubmed
Ulrich D, Hrynyschyn K, Pallua N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease. Plast Reconstr Surg. 2003;112:1279-86 pubmed
product information
master code :
DTM200
SKU :
DTM200
product name :
Human TIMP-2 Quantikine ELISA Kit
unit size :
1 Kit
description :
The Human TIMP-2 Quantikine ELISA Kit from R&D Systems is a Solid Phase Sandwich ELISA that quantifies human TIMP-2 in cell culture supernates (50 ul), serum (10 ul), edta plasma (10 ul), heparin plasma (10 ul), saliva (10 ul), urine (25 ul).
target :
TIMP-2
category :
ELISAs
species :
Human
specificity :
Natural and recombinant human TIMP-2. This assay detects approximately 50% of recombinant human TIMP-2 when complexed with recombinant human active MMP-9 in a 1:1 molar ratio.
gene symbol :
TIMP2
kit type :
Solid Phase Sandwich ELISA
assay length :
4.5 hours
elisaSampleTypes :
Cell Culture Supernates (50 uL), Serum (10 uL), EDTA Plasma (10 uL), Heparin Plasma (10 uL), Saliva (10 uL), Urine (25 uL)
elisaSensitivity :
0.064 ng/mL
elisaRange :
0.16 - 10 ng/mL
top caption :
Human TIMP-2 ELISA Cell Culture Supernate/Saliva/Urine Standard Curve
applications :
ELISA
USD :
655 USD
product details :
The Quantikine Human TIMP-2 Immunoassay is a 4.5 hour solid phase ELISA designed to measure TIMP-2 levels in cell culture supernates, serum, plasma, and saliva. It contains CHO cell-expressed recombinant human TIMP-2, and antibodies raised against the recombinant protein. Natural human TIMP-2 showed dose-response curves that were parallel to the standard curves obtained using the recombinant Quantikine kit standards, indicating that this kit can be used to determine relative levels of natural human TIMP-2.
alt names :
CSC-21Ktissue inhibitor of metalloproteinase 2, metalloproteinase inhibitor 2, TIMP metallopeptidase inhibitor 2, TIMP2, TIMP-2, Tissue inhibitor of metalloproteinases 2
storage :
Store the unopened product at 2 - 8 ░C. Do not use past expiration date.
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.